Calls for papers
-
Oragenics has announced a new license agreement with Inspirevax (formerly Biodextris) for use of Inspirevax’s BDX301 intranasal mucosal adjuvant in Oragenic’s NT-CoV2-1 intranasal COVID-19 vaccine candidate. The company said that the deal includes payments for… Read more . . .
-
According to Vistagen, the US Patent and Trademark Office (USPTO) has granted US Patent 11,419,881 covering the company’s PH80 pherine nasal spray for treatment of migraine until 2040. The company says that “PH80 is an investigational pherine nasal… Read more . . .
-
Bryn Pharma has presented data from a bioavailability study of its Utuly epinephrine nasal spray demonstrating that 13.2 mg dose of Utuly absorbed as fast and produced higher and longer-lasting epinephrine plasma levels than a… Read more . . .
-
Aerami Therapeutics announced that it will develop its AER-901 nebulized imatinib for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in addition to pulmonary arterial hypertension (PAH). The FDA granted orphan drug designation to AER-901… Read more . . .
-
According to ARS Pharmaceuticals, Recordati has returned the European marketing rights to ARS-1 epinephrine nasal spray (Neffy) in return for an unspecified amount up front plus future milestone payments connected to European approval and launch… Read more . . .
-
Impel Pharmaceuticals announced that it will cut 16% of its workforce and halt development of INP105 intranasal olanzapine for the treatment of agitation in autism spectrum disorder. The company also said that its Chief Medical Officer,… Read more . . .
-
Israeli biotech BiomX has announced data from the first part of a Phase 1b/2a trial of the company’s BX004 nebulized phage cocktail for the treatment of P. aeruginosa lung infections in cystic fibrosis patients demonstrating a… Read more . . .
-
Firebrick Pharma announced that it has filed a Pediatric Investigation Plan (PIP) with the EMA’s Pediatric committee for its Nasodine povidone-iodine nasal spray as the company plans to submit a marketing application for Nasodine by… Read more . . .
-
Optinose announced that it has submitted an sNDA for a label expansion of Xhance fluticasone propionate nasal spray (OPN-375) for the treatment of chronic sinusitis without nasal polyps. Xhance has been approved for the treatment of… Read more . . .
-
Beckley Psytech said that the FDA has approved the company’s IND for a Phase 2b study comparing 2 doses of BPL–003 intranasal dry powder synthetic 5-MeO-DMT (mebufotenin) in patients with treatment-resistant depression. According to Beckley Psytech,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK